drugset
drugset / Trial / NCT06346912

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

NCT06346912 ↗

Phase 0 Recruiting 20 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Timeline

Start
2024-05-30
Primary completion
2027-05-30
Completion
2027-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19-BAFF Targeted CAR T-cells Cell therapy — Intravenous

Indications

B-cell acute lymphoblastic leukemia